Vancomycin-Induced DRESS Syndrome: An Important Concern in Orthopedic Surgery

Littlehales, Emma; Murray, Odhrán; Dunsmuir, Robert

doi:10.1155/2018/1439073

Cited by 7 publications

(8 citation statements)

References 14 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Kardaun et al reported a considerably lower rate in the acute phase, probably reflecting bias in published retrospective studies [12]. Fulminant hepatitis is the main cause of death associated with this syndrome, occurring in 5 to 10% of cases [13]. Myocarditis and respiratory failure are other main causes of death [10].…”

Section: Introductionmentioning

confidence: 99%

Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review

Sharifzadeh

Mohammadpour

Tavanaee

et al. 2020

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Background Drug reaction with eosinophilia and systemic symptoms syndrome (DRESS) is a delayed infrequent potentially lifethreatening idiosyncratic drug reaction. Aromatic anticonvulsants and allopurinol are the most frequent causative agents. However, various reports of antibiotic-induced DRESS are available. In this review, we try to summarize reports of antibacterial antibiotic-induced DRESS focusing on characteristics of DRESS induced by each antibiotic group. Methods The data were collected by searching PubMed/MEDLINE and ScienceDirect. The keywords used as search terms were "DRESS syndrome," "drug-induced hypersensitivity syndrome (DIHS)," "antibiotics," "antimicrobial," and names of various antimicrobial groups. Finally, 254 relevant cases with a definite or probable diagnosis of DRESS based on RegiSCAR criteria were found until 30 May 2020 and reviewed. Results and conclusion Totally, 254 cases of antibacterial antibiotic-induced DRESS are reported. Most of them are related to antituberculosis drugs, vancomycin, and sulfonamides, respectively. Rash and fever were most frequent clinical findings. Eosinophilia and liver injury were the most reported hematologic and visceral organ involvement, respectively. Most of the patients are managed with systemic corticosteroids. The death occurred in 16 patients which most of them experienced liver or lung involvement. The reactivation of various viruses especially HHV-6 is reported in 33 cases. The mean latency period was 29 days. It is necessary to perform thorough epidemiological, genetic, and immunological studies, also systematic case review and causality assessment, as well as well-designed clinical trials for better management of antibiotic-induced DRESS.

show abstract

Section: Introductionmentioning

confidence: 99%

Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review

Sharifzadeh

Mohammadpour

Tavanaee

et al. 2020

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…Vancomycin exposure is associated with the development of several forms of delayed-type adverse event. Of particular concern is drug reaction with eosinophilia and systemic symptom (DRESS), which has a delayed onset (2–6 weeks) and is characterized by fever, eosinophilia, renal impairment, severe skin reactions, lymphadenopathy, and/or liver dysfunction ( Konvinse et al , 2019 ; Littlehales et al , 2018 ; Minhas et al , 2016 ). CD4+ and CD8+ T cells activated by a range of drugs have been detected in blood of patients with DRESS ( Mauri-Hellweg et al , 1995 ; Zhao et al , 2019 ).…”

mentioning

confidence: 99%

Deciphering Adverse Drug Reactions:In VitroPriming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01

Ogese

Lister

Gardner

et al. 2021

Toxicological Sciences

View full text Add to dashboard Cite

Drug rash with eosinophilia with systemic symptoms (DRESS) is a serious adverse event associated with use of the glycopeptide antibiotic vancomycin. Vancomycin-induced DRESS is associated with the expression of HLA-A*32:01, suggesting that the drug interacts with this HLA to activate CD8+ T-cells. The purpose of this study was to utilize PBMC from healthy donors to: (i) investigate whether expression of HLA-A*32:01 is critical for the priming naïve of T-cells with vancomycin and (ii) generate T-cell clones (TCC) to determine whether vancomycin exclusively activates CD8+ T-cells and to define cellular phenotype, pathways of drug presentation and cross-reactivity. Dendritic cells were cultured with naïve T-cells and vancomycin for 2 weeks. On day 14, cells were re-stimulated with vancomycin and T-cell proliferation was assessed by [3H]-thymidine incorporation. Vancomycin-specific TCC were generated by serial dilution and repetitive mitogen stimulation. Naïve T-cells from HLA-A*02:01 positive and negative donors were activated with vancomycin; however the strength of the induced response was significantly stronger in donors expressing HLA-A*32:01. Vancomycin-responsive CD4+ and CD8+ TCC from HLA-A*32:01+ donors expressed high levels of CXCR3 and CCR4, and secreted IFN-γ, IL-13 and cytolytic molecules. Activation of CD8+ TCC was HLA class I-restricted and dependent on a direct vancomycin HLA binding interaction with no requirement for processing. Several TCC displayed cross-reactivity with teicoplanin and daptomycin. To conclude, this study provides evidence that vancomycin primes naïve T-cells from healthy donors expressing HLA-A*32:01 through a direct pharmacological binding interaction. Cross-reactivity of CD8+ TCC with teicoplanin provides an explanation for the teicoplanin reactions observed in vancomycin hypersensitive patients.

show abstract

“…Table 3 and Table 4 present a summary and analysis of 44 cases of eosinophilia caused by vancomycin. 2–8,35–65 Of these 44 cases, drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug-induced hypersensitivity syndrome, was found in 35 cases. 2–8,35–57 In other cases, some patients had increased eosinophil counts an...…”

Section: Discussionmentioning

confidence: 99%

A rare case of infant eosinophilia induced by oral vancomycin: a case report and literature review

Yin

Guo

et al. 2023

J Int Med Res

View full text Add to dashboard Cite

Oral vancomycin is mainly used to treat and prevent active Clostridium difficile infection. Because it is widely believed that there is a very low absorption rate via the gastrointestinal tract, reports of adverse reactions following oral vancomycin administration are rare. This case report describes for the first time a case of antibiotic-associated diarrhoea in a 2-month-old infant treated with oral vancomycin. After oral vancomycin treatment, the number of eosinophils increased significantly and the levels gradually recovered after drug withdrawal. A review and analysis of the previously reported adverse reactions caused by oral vancomycin and eosinophilia caused by vancomycin confirm the need for physicians to pay close attention to vancomycin-related adverse reactions, to monitor the required concentration and to measure eosinophil counts in patients with rash-related adverse reactions. Patients with concomitant diseases and children should be monitored for adverse events as it is possible that they have increased gastrointestinal absorption of vancomycin following oral administration. When vancomycin causes eosinophilia, fever and rash, physicians should be alert to the possibility of organ damage.

show abstract

Vancomycin-Induced DRESS Syndrome: An Important Concern in Orthopedic Surgery

Cited by 7 publications

References 14 publications

Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review

Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review

Deciphering Adverse Drug Reactions:In VitroPriming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01

A rare case of infant eosinophilia induced by oral vancomycin: a case report and literature review

Contact Info

Product

Resources

About